Silver Nitrate vs. Triamcinolone for Treatment of Hypergranulation Tissue
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorFrancesco Egro
About this trial
This randomized controlled trial aims to compare the efficacy of silver nitrate, triamcinolone, and a successive use of both treatments in managing hypergranulation tissue in traumatic wounds. Conducted over a four-year period at UPMC Mercy, the study will involve patients presenting with hypergranulation tissue. Participants will be randomly assigned to receive either topical silver nitrate, topical triamcinolone, or a combination of the two in succession. The study will assess treatment outcomes based on the reduction or resolution of hypergranulation tissue, with the goal of identifying the most effective therapeutic approach. This research will provide valuable insights into optimizing treatment strategies for hypergranulation tissue in traumatic wounds.
Eligibility criteria
Qualifiers
Patients must be 18 years or older.
Patients must be admitted to the institution with non-infected, traumatic wounds exhibiting hypergranulation tissue.
Patients must provide consent to participate in the study.
Eligible wounds include superficial or partial-thickness wounds.
Disqualifiers
Patients with known allergies or contraindications to silver nitrate or triamcinolone.
Patients with wounds that do not exhibit hypergranulation tissue.
Patients with wounds not primarily due to traumatic injury (e.g., surgical wounds, pressure ulcers).
Full-thickness, infected, or complex wounds will be excluded, as these may require different management strategies.
Trial design
Treatments tested in this trial
- Silver Nitrate
- triamcinolone
- Silver nitrate + triamcinolone
Treatment groups
270 Participants
are divided into 3 treatment groupsSponsors and collaborators
Francesco Egro
Lead sponsor
University of Pittsburgh
Sponsor institution
Source ClinicalTrials.gov